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558Objective: We sought to investigate the safety and feasibility of obtaining total respiratory support during 72
hours using a pump-driven (Levitronix CentriMag; Levitronix LLC, Waltham, Mass) venous–venous extracor-
poreal lung membrane (Novalung; Novalung GmbH, Hechingen, Germany) attached through a single double-
lumen cannula (Novalung) into the femoral or jugular vein in pigs.
Methods: Twelve pigs were initially mechanically ventilated for 2 hours (respiratory rate, 20–25 breaths/min;
tidal volume, 10–12 mL/kg; fraction of inspired oxygen, 1.0; positive end-expiratory pressure, 5 cm H2O). There-
after, the extracorporeal lung membrane was attached to the right femoral (n¼ 6, 26F) or jugular (n¼ 6, 22F) vein
by using a single double-lumen cannula placed transcutaneously. Ventilatory settings were then reduced to near-
apneic ventilation (respiratory rate, 4 breaths/min; tidal volume, 1–2 mL/kg; fraction of inspired oxygen, 0.21;
positive end-expiratory pressure, 10 cm H2O), and pump flow was increased hourly until maximal efficacy. Blood
gases and hemodynamics were measured hourly, and lung and plasma cytokine levels were measured every 4
hours.
Results: The device’s mean blood flow was 2.16 0.43 L/min, permitting an oxygen transfer and carbon dioxide
removal of 203.6  54.6 and 590.3  23.3 mL/min, respectively. Despite static ventilation, all pigs showed op-
timal respiratory support, with a PaO2, PaCO2, and mixed venous oxygen saturation of 226.2  56.4, 59.7  8.8,
and 85.6 5.3 mm Hg, respectively. There were no significant inflammatory, cellular, or coagulatory responses;
lung cytokine levels remained in the normal range. Route (femoral vs jugular) or size (22F vs 26F) of the cannula
did not change hemodynamic or respiratory parameters significantly.
Conclusions: This circuit provides total respiratory support over 72 hours without inducing significant hemody-
namic, coagulatory, cellular, or inflammatory responses. (J Thorac Cardiovasc Surg 2010;140:558-63)Supplemental material is available online.Video clip is available online.In contrast to advances in the development of cardiac sup-
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The Journal of Thoracic and Cardiovascular Surgmechanical systems for failing lungs has lagged far behind.
Novalung (Novalung GmbH, Hechingen, Germany) is
a pumpless extracorporeal respiratory assist device includ-
ing a low-resistance heparin-bonded membrane that, once
attached to the femoral vessels, allows an arterial–venous
gas exchange with the cardiac pump as the driving force.
The membrane removes almost all carbon dioxide, and
this in turn permits the reduction of the mechanical ventilator
settings beyond the ARDSnet guidelines, thus minimizing
ventilator-induced lung injury and giving the native lungs
time to heal.1–6 Unfortunately, because of the low driving
blood flow (1–2 L/min) perfusing the device, oxygenation
is limited, and evidence now exists that distal perfusion of
the cannulated limbs represents a clinical issue.
To improve this and because profound hypoxemia might
become the prominent indication of extracorporeal support
for high-mortality-risk respiratory failure, we investigated
whether a single double-lumen venous cannula and mag-
netic centrifuged pump (Levitronix CentriMag Blood
Pump; Levitronix LLC, Waltham, Mass)7 coupled with the
Novalung device would provide complete respiratory
support in a healthy pig model and determined the magni-
tude of its inflammatory, blood cell trauma coagulation
response.ery c September 2010
Abbreviations and Acronyms
ACT ¼ activated clotting time
BAL ¼ bronchoalveolar lavage
CaO2 ¼ oxygen content
ECMO ¼ extracorporeal membrane oxygenation
FIO2 ¼ fraction of inspired oxygen
IL ¼ interleukin
PEEP ¼ positive end-expiratory pressure
PIP ¼ peak inspiratory pressure
RR ¼ respiratory rate
VT ¼ tidal volume
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Twelve Yorkshire Duroc pigs (Isoquimen S/L, Barcelona, Spain) weigh-
ing 59.3 6.18 kg were used. All animals received care in compliance with
the ‘‘Principles of Laboratory Animal Care’’ formulated by the National
Society for Medical Research and the ‘‘Guide for the Care and Use of
Laboratory Animals’’ prepared by the Institute of Laboratory Animal Re-
sources, National Research Council and published by the National Acad-
emy Press (revised 1996). The study was approved by the Institutional
Animal Care and Use Committee of the University of Barcelona, with strict
adherence to the Institutional Animal Care and Use Committee guidelines
regarding humane use of animals (project N-001-61399030-F).
Study Design
The study working plan is depicted in Figure E1. Animals were intubated
and initially underwent volume-controlled ventilation (respiratory rate [RR],
20 breaths/min; tidal volume [VT], 10 mL/kg; fraction of inspired oxygen
[FIO2], 1.0; and positive end-expiratory pressure [PEEP], 5 cm H2O) with
a mechanical ventilator (Servo 900D; Siemens, Munich, Germany) followed
by 2 hours of stabilization. Animals were then randomly assigned to cannu-
lation either through the femoral (n¼ 6) or jugular (n¼ 6) veins through the
double-lumen caval cannula (see Figure E2) connected with the Novalung
membrane and the Levitronix CentriMag pump (see Figure E3 and Video
E1). Starting with a minimal (0.1–0.2 L/min) pump flow, the ventilator set-
tings were reduced to reach near-static or near-apneic ventilator settings (RR,
4 breaths/min; VT, 1–2 mL/kg; FIO2, 0.21; PEEP, 10 cm H2O) and thereby
permissive hypercapnia. Once reached, the pump blood flows were increased
by 0.5 L/min continuously to reach 2 L/min, which was sufficient in our pre-
liminary experience to provide complete gas exchange. Pump flow was in-
creased thereafter in a stepwise fashion at 1-hour intervals to reach the
most efficient flow for the most effective gas exchange (exploratory phase).
Animals were then monitored to examine the physiological and biological
influence of the system for a total of 72 hours (monitoring phase).
A real-time flowmeter (Novalung GmbH) measured the extracorporeal
flow through the device by using an ultrasonic flow probe (Sono TT ultra-
sonic flowmeter; Emtech GmbH, Finning, Germany). Device malfunction
was defined by the occurrence of a blood flow of less than 0.5 L/min or
if a 50% blood flow reduction was noted. Activated clotting time (ACT)
was maintained at approximately 180 to 200 seconds (an alternative was
an activated partial thromboplastin time of 50–60 seconds) by using a con-
tinuous heparin infusion and checked every 2 hours. Excessive bleeding or
low blood flow caused by malposition of the cannula required reinterven-
tion. The capability of the device to provide additional oxygen was mea-
sured by calculating the oxygen content (CaO2) of blood entering and
exiting the Novalung iLA membrane and multiplying the difference
by the flow rate through the device, according to the following formulas:
CaO2 ¼ (Hemoglobin 3 1.31 3 SaO2)þ (PaO2 3 0.003); Oxygen transferThe Journal of Thoracic and Ca(mL/min) ¼ [CaO2 after iLA  CaO2 before iLA) 3 Device flow rate
(L/min) 3 10. The arteriovenous extracorporeal carbon dioxide removal
(AVCO2R) provided by the device was calculated as follows: AVCO2R
(mL/min)¼ CO2 content in the inflow cannulaCO2 content in the outflow
cannula (mL CO2/mL blood) 3 Blood flow iLA (L/min) 3 10.5.
During the exploratory phase, respiratory parameters and hemodynamics
(through a SwanGanz catheter) were registered hourly, as were hemato-
logic parameters. Biological values (cytokines in blood plasma and bron-
choalveolar lavage [BAL] fluid) were registered at the moment of
intubation and placement of the artificial lung system and then 6 hours after
intubation of the pig. During the monitoring phase, all parameters were mea-
sured and recorded every 4 hours, and biological parameters were measured
every 12 hours. All data measured before initiation of the extracorporeal
support were set as baseline values.
Anesthesia and Monitoring
Yorkshire Duroc pigs were received and quarantined for at least 1 week
before the operation. Selection was based on results of physical examina-
tions and body weight. Animals were premedicated with azaperone as a sed-
ative (4 mg/kg administered intramuscularly) and thiopental as a hypnotic
(10 mg/kg administered intravenously; B. Braun, Medical S.A., Rubi, Bar-
celona, Spain) through ear veins. Animals were placed on the surgical table
in the supine position, and induction anesthesia was performed with propo-
fol (Diprivan, AstraZeneca, Wilmington, Del), 5 mg/kg administered
intravenously, and fentanyl (Fentanest; Kern Pharma, Barcelona, Spain),
5 mg/kg administered intravenously. For relaxation, 6 mg $ kg1 $ h1 of
rocuronium bromide (Esmeron; Schering–Plough, Kenilworth, NJ) was ad-
ministered intravenously. Animals were intubated orotracheally with a 7.5F
endotracheal tube and mechanically ventilated with insertion of a nasogas-
tric tube. Anesthesia was maintained with continuous endovenous infusion
of fentanyl (1 mg $ kg1 $ h1) and propofol (3–5 mg $ kg1 $ h1) until the
study’s end. At the time of instrumentation, intravenous cefazolin (1 g) was
administered and then every 3 hours thereafter. Inotropic and vasoactive
drugs (noradrenaline, 4 mg in 250 mL of 5% glucosaline solution at
5 mL/h administered intravenously) were used if necessary. A loading
dose of heparin was administered before the single double-lumen cannula
insertion (150 IU/kg) and every 2 hours (50 U/kg) thereafter to prevent
vessel clotting (targeting activated partial thromboplastin time, 50–60;
ACT, 180–200).
Fluid management was standardized by using continuous infusion of
0.9% NaCl at a rate of 100 mL/h with the following exceptions. First, if
mean arterial pressure was less than 60 mm Hg or central venous pressure
was less than 8 mm Hg, an additional 100 mL of colloid solution was infused
over 1 minute. Second, if central venous pressure was greater than 10 mm Hg,
the continuous infusion was stopped until it returned to within the goal range
of 8 to 10 mm Hg. Atropine (0.5–1 mg administered intravenously) was ad-
ministrated if cardiac frequency was less than 50 beats per minute.
Animals were initially mechanically ventilated with the following set-
tings, followed by 2 hours of stabilization: VT of 10 mL/kg, minute volume
of 11 L/min, RR of 20 breaths/min, peak inspiratory pressure (PIP) of 30 cm
H2O or less, FIO2 of 1.0, and PEEP of 5 cm H2O. After stabilization, the
double-lumen cannula was inserted, and the Novalung with the Levitronix
CentriMag Blood Pump system was attached at a flow level of 0.1 to 0.2 L/
min for 30 minutes. Thereafter, the ventilator settings were reduced gradu-
ally to reach static or passive ventilator settings: RR, 4 or fewer breaths/min,
confirming a PIP of less than 15 cm H2O; VT, 1 to 2 mL/kg; FIO2, 0.21; and
PEEP, 10 cm H2O. During the 2-hour stabilization period, measurement
catheters were inserted, and blood samples were taken.
Respiratory Parameters and Hemodynamics
Respiratory parameters. The following parameters were recorded
hourly until the best blood pump flow was decided, and afterward, param-
eters were recorded every 4 hours. Ventilator settings were as follows: VT
(in milliliters per kilogram), minute volume (in liters per minute), PEEPrdiovascular Surgery c Volume 140, Number 3 559
TABLE 1. Pigs’ mechanical ventilatory settings and hemodynamic
data during initial ventilation (2 hours) and apneic ventilation under
extracorporeal support (72 hours)
Variables
Initial ventilation
without
extracorporeal
support
Apneic ventilation
with extracorporeal
support
P
value
VT (mL) 537  68 115  13 .05
RR (breaths/min) 20  0 4  0 .05
MV (L/min) 10.7  1.4 0.4  0.05 .05
CI (L $ min1 $ m2) 4.8  0.6 5.1  0.9 NS
MAP (mm Hg) 113  9.9 95.4  12.6 NS
MPAP (mm Hg) 24  5.7 34.4  3.1 NS
SVR (dyne/cm5) 872  252.4 1073  273.2 NS
PVR (dyne/cm5) 120.8  14.3 188  40.6 NS
PCWP (mm Hg) 15.3  1.75 16.9  2.4 NS
CVP (mm Hg) 11.5  2.3 12.4  2.5 NS
VT, Tidal volume; RR, respiratory rate; MV, minute volume; CI, cardiac index; NS, not
significant; MAP, mean arterial pressure; MPAP, mean pulmonary arterial pressure;
SVR, systemic vascular resistance; PVR, pulmonary vascular resistance; PCWP,
pulmonary capillary wedge pressure; CVP, central venous pressure.
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and FIO2. Gas exchange was as follows: PaO2 (in millimeters of mercury),
PaCO2 (in millimeters of mercury), CaO2 (in milliliters per deciliter), content
of carbon dioxide (in milliliters per deciliter), pH, alveolar-arterial oxygen
difference (DA-aO2), PaO2/FIO2, end-tidal carbon dioxide, oxygen consump-
tion, oxygen delivery, intrapulmonary shunt or venous admixture, mixed
venous oxygen content, mixed venous carbon dioxide content, and ventila-
tory efficiency index. Mechanical respiratory function was determined as
follows: static respiratory system compliance, chest wall compliance, and
lung compliance.
Hemodynamic parameters. All animals were instrumented with
an arterial pressure line (5F) placed transcutaneously in the left femoral ar-
tery, multiple peripheral venous catheters, and a Swan–Ganz catheter (Ed-
wards Lifesciences, Munich, Germany). The following hemodynamic
variables were monitored (Hewlett Packard model 685): heart rate (in beats
per minute); cardiac output (in liters per minute); cardiac index (in liters per
minute per square meter); systolic, diastolic, and mean arterial pressure (in
millimeters of mercury); systolic, diastolic, and mean pulmonary artery
pressure (in millimeters of mercury); pulmonary capillary wedge pressure
(in millimeters of mercury); central venous pressure (in millimeters of
mercury); systolic index (in milliliters per square meter); systolic volume
(in milliliters); systemic vascular resistance (Dynes [DS] cm2)/index sys-
temic vascular resistance (DS m2/cm2); vascular pulmonary resistance
(DS/cm2)/index vascular pulmonary resistance (DS m2/cm2); left ventricu-
lar stroke work/index (in [g-m]/[g-m/m2]); and right ventricular stroke
work/index (in [g-m]/[g-m/m2]). Body temperature (in degrees Celsius)
was measured with a Swan–Ganz catheter and was maintained at 37C
with a heater and blankets. A pulse oximeter (BCI, Inc, Waukesha, Wis),
placed on the pig’s tail, measured peripheral arterial saturation as a percent-
age. Urine output was monitored with a percutaneous bladder catheter.Evaluation of Blood Cell Trauma, Coagulation, and
Inflammatory Response
For evaluation of hemolysis, lactate dehydrogenase, potassium, and hap-
toglobin were controlled every 4 hours. Hemotologic parameters, arterial
blood gases, hematocrit, hemoglobin, leukocyte and thrombocyte counts,
Na, Cl, complete blood count, and ACT were evaluated in the same manner.
The values of interleukin (IL) 1b, IL-6, IL-8, IL-6 receptor, and tumor ne-
crosis factor a were measured by means of BAL and plasma samples to
evaluate systemic and pulmonary inflammatory responses. BAL samples
were taken in sterile conditions with 50 mL of normal saline. The first
BAL was performed after intubation and before starting mechanical venti-
lation. The second and third BAL samples were obtained during installation
of the extracorporeal lung assist device and 6 hours afterward, and thereaf-
ter, BAL sample were taken every 12 hours. Blood samples to identify
cytokines were taken in the same manner. Blood and BAL samples were
centrifuged between 2000 and 3000 rpm for 15 minutes and stored at70C.
Postmortem Analysis
After 72 hours of observation, animals were killed immediately at the
minimum vital distress in deep sedation. Before euthanasia, heparin (100
IU/kg) was administered to avoid postmortem thrombus formation. Eutha-
nasia was induced with an overdose of potassium chloride (40 mEq by
means of rapid intravenous administration). At autopsy, the heart and the
lung were removed to evaluate the presence of emboli or thrombi and struc-
tural heart abnormalities or grade of inflammation in the lung. Any gross
pathologic findings were photographed and documented.
The lung and heart tissue samples were fixed in 10% formol, sent to
the department of histopathology, and embedded in paraffin after routine
follow-up procedures. Vessels with grafts were checked for signals of re-
vascularization in the graft or evidence of emboli or thrombi in cannu-
lated vessels. All devices were evaluated for infection and mechanical
properties.560 The Journal of Thoracic and Cardiovascular SurgStatistical Analysis
All data were reported as means standard deviations. Data were double
entered and checked with an SPSS-12 program (SPSS, Inc, Chicago, Ill).
Means, proportions, standard deviations, and 95% confidence intervals
were calculated from every study variable. Parameters were statistically an-
alyzed by means of 1-way analysis of variance for repeated measures to
compare values with baseline. Odds ratio were calculated, with a 2-tailed
P value of .05, to compare categorical variables. Analysis used the statistical
package SPSS-12.RESULTS
All animals completed the study protocol, and all cannu-
lations were made with Seldinger’s technique. The mean
blood flow through the lung membrane was 2.16  0.43
L/min. All pigs showed optimal respiratory support during
the study period, despite static ventilation, with mean
PaO2, PaCO2, and mixed venous oxygen saturation values
of 226.2 56.4, 59.7 8.8, and 85.6 0.3 mm Hg, respec-
tively. There was no vasoactive drug requirement to main-
tain hemodynamic stability (Table 1). The device allowed
a mean oxygen transfer and carbon dioxide removal of
203.6  54.6 mL/min and 590.3  23.3 mL/min, respec-
tively (Figure 1). There were no significant differences in
outcome between femoral and jugular cannulation or be-
tween cannula sizes (Table 2).
Animals did not have any significant cellular trauma or co-
agulatory alteration over the 72 hours (Table 3). Figures 2
and 3 show the evolution of lung and plasma cytokine
levels during the study, and no significant changes were
found during the study. Finally, results of pathological
examinations were normal in all specimens, and
microbiological evaluation of the circuits was negative.
Evaluation of all devices after the study’s end did not show
any protein leak across the membrane.ery c September 2010
FIGURE 1. Correlation between oxygen transfer and carbon dioxide re-
moval (CO2R) and blood flow perfusing the interventional lung assist device
during apneic ventilation (AV).
TABLE 3. Cellular trauma and coagulatory evaluation without and
with extracorporeal support
Variables
Without
extracorporeal
support
With
extracorporeal
support P value
LDH (IU/L) 1001  190.2 881.93  196.99 NS
Kþ (mEq/L) 3.86  0.26 3.82  0.56 NS
Haptoglobin (g/L) 0.20  0.092 0.22  0.094 NS
Hemoglobin (g/L) 83.16  8.72 75.53  10.14 NS
Hematocrit (L/L) 0.27  0.04 0.25  0.03 NS
PT (s) 11.74  1.89 11.71  1.50 NS
Data express the mean values of the different time scales measured in the 2 groups.
LDH, Lactate dehydrogenase; NS, not significant; Kþ, potassium; PT, prothrombin
time.
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Developments of new mechanical circulatory support de-
vices in the last decades have allowed an improvement in the
prognosis of patients with acute or chronic respiratory fail-
ure. Extracorporeal membrane oxygenation (ECMO) is the
most known extracorporeal system used thus far and pro-
vides both cardiac and respiratory support for severely dis-
eased patients. The venous–venous ECMO does not
provide cardiac support but does provide sufficient oxygen-
ation for several weeks, allowing diseased lungs to heal
while any potential additional injury of mechanical ventila-
tion is avoided. It has become the standard treatment of re-
spiratory failure in newborn and pediatric patients who do
not respond to conventional therapy, but because of the
high technical demands, perceived cost, and risk of compli-TABLE 2. Hemodynamic and respiratory parameter comparisons
between jugular vein cannulation and femoral vein cannulation
Variables
Jugular vein
(22F cannula)
Femoral vein
(26F cannula) P value
VTa (mL) 113  16 116  13 NS
RRa (breaths/min) 4  0 4  0 NS
MVa (L/min) 0.45  0.05 0.46  0.05 NS
FlowM (L/min) 2.13  0.50 2.19  0.32 NS
CI (L $ min1 $ m2) 5.15  0.67 5.19  1.14 NS
MAP (mm Hg) 93.52  13.22 97.90  11.45 NS
MPAP (mm Hg) 34.63  3.73 34.15  2.25 NS
SVR (dyne/cm5) 1001  214.6 1140  246.5 NS
PVR (dyne/cm5) 174.77  38.43 200.81  37.64 NS
PCWP (mm Hg) 17.28  2.08 16.54  2.67 NS
CVP (mm Hg) 12.93  2.38 11.77  2.54 NS
VTa, Tidal volume in apneic ventilation; NS, not significant; RRa, respiratory rate in
apneic ventilation; MVa, minute volume in apneic ventilation; FlowM, mean blood
flow; CI, cardiac index; MAP, mean arterial pressure; MPAP, mean pulmonary arterial
pressure; SVR, systemic vascular resistance; PVR, pulmonary vascular resistance;
PCWP, pulmonary capillary wedge pressure; CVP, central venous pressure.
The Journal of Thoracic and Cacations (eg, bleeding), ECMO has been less successful in
adults.8,9-11
The Novalung iLA device is a relatively new, commer-
cially available, low-resistance-membrane lung with tight
diffusion membranes and a protein matrix coating incorpo-
rating a gas exchange surface of 1.3 m2. This device has
been used successfully to allow and optimize advanced
lung-protective ventilation strategies beyond ARDSnet12
in an arteriovenous pumpless way in patients with adult re-
spiratory distress syndrome4,13 and carbon dioxide retention
syndromes without ventilator-associated lung injury in re-
covery from lung injuries and as a bridge to transplanta-
tion.6,14,15 The minimal oxygen transfer is an obvious
limitation of the pumpless arteriovenous attachment
mode.16,17 Ischemia of a lower limb caused by femoral
arterial cannulation is another concern, being the most
common complication (5.9% to 11%) of the iLA
device.18,19 In our study the single double-lumen cannula
placed in a venous manner avoided this effect, not observing
episodes of ischemia of lower extremities. On the other
hand, as we commented previously, the iLA device in pump-
less mode does not achieve sufficient blood oxygenationFIGURE 2. Correlation between mean plasma cytokine values and time.
TNF, Tumor necrosis factor; IL, interleukin.
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FIGURE 3. Correlation between mean lung cytokine values and time.
TNF, Tumor necrosis factor; IL, interleukin.
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the one we used allowed us to increase the blood flow and
obtain an optimal oxygenation (PaO2 of 226.2  56.4) de-
spite near-apneic ventilation and room air FIO2.
We used a single double-lumen cannula placed in the fem-
oral–jugular veins where one lumen drains blood and one re-
turns oxygenated blood. To place a unique cannula has
different advantages. One is to avoid any vessel manipula-
tion (eg, vascular lesion, bleeding focus, and problems
with cannulation), and another is that it allows a shorter cir-
cuit. Because this second benefit maintained a physiological
body temperature (36.4C  0.3C) over time (72 hours in
our study), the circuit did not need a blood-holder line.
Also, no pig required volume support or vasoactive drugs
to maintain hemodynamic stability because of low blood
loss inside the circuit (Table 1). The end of the cannula
was placed through the femoral vein and was below the renal
vein’s takeoff, not hindering renal venous drainage without
an effect on the function of this organ; the length of the can-
nula was enough to permit an appropriate blood circuit and
gas exchange, and there were no differences between femo-
ral (26F) and jugular (22F) vein cannulation. The only thing
to highlight on the cannula prototype used is that it is diffi-
cult to place with Seldinger’s technique because of its
length, which makes it difficult to hinder the final leg of
its introduction. We propose for future studies to change
its structure, such as its distal end, to facilitate its sliding
on the vessel.
The Levitronix CentriMag Blood Pump is a third-
generation blood pump with a magnetic bearing. This
pump is based on the ‘‘bearingless motor’’ technology,
which combines the drive, magnetic bearing, and rotor func-
tions into a single unit. The motor generates the magnetic
bearing force and torque necessary to produce the unidirec-
tional flow. The absence of bearings and seals results in min-
imal friction or heat generation in the blood path and562 The Journal of Thoracic and Cardiovascular Surgminimum blood cell damage. Another advantage of this
pump is the absence of a blood pool, minimizing the cell
trauma and coagulation alterations; it also does not require
a blood heater.
In conclusion, the venous–venous, pump–driven, extra-
corporeal lung membrane, single double-lumen cannula sys-
tem is an effective provider of total respiratory support over
72 hours in a healthy pig model without inducing hemody-
namic, coagulatory, cellular, or inflammatory imbalances
and can be placed either in the jugular or femoral veins. Pa-
tients with acute or chronic lung failure who present with se-
vere hypoxemia, hemodynamic instability, or important
arteriopathy and cannot benefit from the extracorporeal arte-
riovenous Novalung pumpless system could benefit from the
investigated circuit.References
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SDiscussion
Dr Joseph B. Zwischenberger (Lexington, Ky). Paulo Mac-
chiarini’s laboratory is to be congratulated as one of a handful in
the world that can do these long-term studies. What they have
done is put together a system with the Novalung double-lumen
catheter, a CentriMag pump, and a Novalung gas exchange device
in which they used catheters in both the internal jugular vein and the
femoral vein to accomplish total gas exchange with only 2 to 3 L of
flow, and these studies lasted for 72 hours.
A double-lumen catheter has been available since the mid-
1980s, when we designed the first double-lumen catheter. It then
became the standard of care for neonates, eventually going into
children and adults. Recently, the Avalon company has developed
the Elite catheter, which allows percutaneous double-lumen ve-
nous–venous gas exchange for total gas exchange.
Therefore what you have to ask yourself is this: What have they
really done here? They have been able to put together what I would
call a successful system. They have taken a gas exchange device,
a pump, and a catheter; put it together in a component system;
and developed a way of providing systemic anticoagulation. With
that system, they are able to accomplish total gas exchange with
minimum inflammatory mediator activation. Although they did
not in this model, the setup does allow the potential for ambulation,
which we consider the holy grail for a bridge to transplantation and
for long-term respiratory support.
Therefore with that in mind, I have a few questions. First of all,
how did you confirm catheter placement? With a double-lumen
catheter, often location is critical in terms of achieving flow. Sec-
ond, how long could you go without having to change out this sys-
tem? Third, please comment on the potential for ambulation
because many of us believe that ambulation is necessary to provide
a bridge to transplantation or long-term recovery.The Journal of Thoracic and CaDr Macchiarini (Barcelona, Spain). Thank you, Jay.
Concerning the first question, we check where it was placed and
whether it was placed correctly with a chest radiograph. Usually the
tip of this cannula comes just below the right renal vein. Therefore
it is fine because it does not go in the right heart. This was con-
firmed as well at the end of the study through autopsies.
As for the third question about ambulatory issues, I think that
this is a prototype. It is not something that we could immediately
put into the clinical scenario. However, I could imagine that the jug-
ular vein access is something that could be used. We would need,
let’s say, a huge pump because the electronics is something that
you cannot move.
I do not remember the second question.
Dr Zwischenberger. How long could you go without a change
out?
Dr Macchiarini. Well, we did it for 3 days. I think that given
that we did not have requirements like vasoactive drugs or that
we did not do blood transfusions and so forth, we can go for at least
1 week or more, and this is the beauty of this system, with a very
low morbidity profile.
Dr Shaf Keshavjee (Toronto, Ontario, Canada). Paulo, how
did you use the catheter when placing it femorally versus placing
it centrally in terms of recirculation in terms of design? Did you
just switch ports?
Dr Macchiarini (Barcelona, Spain). No, it probably did not
show up in the slides, but we just randomly assigned one pig or
the other to jugular or femoral vein access.
Dr Keshavjee. To clarify, I mean in terms of recirculation of ox-
ygenated return with venous blood.
Dr Macchiarini. We evaluated the venous oxygenation to see
whether this mixing would induce hypoxic vasoconstriction, and
the values were greater than 80%. Therefore this is another issue
that we were able to avoid, and the fact is that a lot of holes
are very close to the tip of the cannula, so the distance between
the tip of the cannula and the pulmonary circulation is very
short, and we did not have any influence on these oxygenation
mixtures.rdiovascular Surgery c Volume 140, Number 3 563
FIGURE E1. Work planning. BAL, Bronchoalveolar lavage; Fio2, fraction of inspired oxygen; RR, respiratory rate; PEEP, positive end-expiratory pressure;
VT, tidal volume.
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FIGURE E2. Photograph of the cannula with magnification of its distal
and proximal parts. The type of blood flowing through the cannula is indi-
cated by red (arterial) and blue (venous) arrows.
FIGURE E3. Schematic image illustrating the entire system function. The
single double-lumen cannula is placed in the right femoral or jugular vein by
using Seldinger’s technique. It drains the venous blood through the pump to
the Novalung gas exchange device and then flows back (oxygenated and
normal levels of carbon dioxide) through the same cannula in the original
vein.
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